Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 60653 [2021-23897]
Download as PDF
<![CDATA[
60653
Federal Register / Vol. 86, No. 210 / Wednesday, November 3, 2021 / Notices
Appendix 3; or (ii) by U.S. government
employees and contract personnel
solely for cybersecurity purposes. The
Commission will not otherwise disclose
any confidential business information in
a manner that would reveal the
operations of the firm supplying the
information.
Summaries of Written Submissions:
The Commission intends to publish
summaries of the positions of interested
persons in this report. If you wish to
have a summary of your position
included in an appendix to the report,
please include a summary with your
written submission and mark the
summary as submitted for that purpose.
The summary may not exceed 500
words, should be in MSWord format or
a format that can be easily converted to
MSWord, and should not include any
confidential business information. The
summary will be published as provided
if it meets these requirements and is
germane to the subject matter of the
investigation. In the report the
Commission will identify the name of
the organization furnishing the
summary and will include a link to the
Commission’s Electronic Document
Information System (EDIS) where the
full written submission can be found.
By order of the Commission.
Issued: October 28, 2021.
Lisa Barton,
Secretary to the Commission.
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 23, 2021,
Nanosyn Inc., 3331 Industrial Drive,
Suite B, Santa Rosa, California 95403–
2062, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
Oxymorphone .................
Fentanyl ..........................
I
9652
9801
Schedule
II
III
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of the above controlled
substances in bulk form. No other
activities for these drug codes are
authorized for this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021–23982 Filed 11–2–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[FR Doc. 2021–23913 Filed 11–2–21; 8:45 am]
BILLING CODE 7020–02–P
[Docket No. DEA–920]
DEPARTMENT OF JUSTICE
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
Drug Enforcement Administration
AGENCY:
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
[Docket No. DEA–921]
Bulk Manufacturer of Controlled
Substances Application: Nanosyn Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Nanosyn Inc. has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTAL
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before January 3, 2022. Such persons
may also file a written request for a
hearing on the application on or before
January 3, 2022.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
VerDate Sep<11>2014
17:01 Nov 02, 2021
Jkt 256001
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Controlled substance
Marihuana Extract .....................
Psilocybin ..................................
Methylphenidate ........................
Levorphanol ..............................
Noroxymorphone ......................
Tapentadol ................................
Drug
code
Schedule
7350
7437
1724
9220
9668
9780
I
I
II
II
II
II
The company plans to import the
listed controlled substances for clinical
trials only. No other activity for these
drug codes is authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021–23897 Filed 11–2–21; 8:45 am]
Fisher Clinical Services, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before December 3, 2021. Such
persons may also file a written request
for a hearing on the application on or
before December 3, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
SUMMARY:
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on August 25, 2021, Fisher
Clinical Services, Inc., 7554 Schantz
Road, Allentown, Pennsylvania 18106–
9032, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–918]
Bulk Manufacturer of Controlled
Substances Application: Groff Global
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Groff Global has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
SUMMARY:
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 86, Number 210 (Wednesday, November 3, 2021)]
[Notices]
[Page 60653]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-23897]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-920]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Fisher Clinical Services, Inc. has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before December 3,
2021. Such persons may also file a written request for a hearing on the
application on or before December 3, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on August 25, 2021, Fisher Clinical Services, Inc., 7554
Schantz Road, Allentown, Pennsylvania 18106-9032, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Marihuana Extract....................... 7350 I
Psilocybin.............................. 7437 I
Methylphenidate......................... 1724 II
Levorphanol............................. 9220 II
Noroxymorphone.......................... 9668 II
Tapentadol.............................. 9780 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
clinical trials only. No other activity for these drug codes is
authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2021-23897 Filed 11-2-21; 8:45 am]
BILLING CODE P
